Health Canada has issued preliminary guidance for companies seeking approval for "subsequent-entry biologics," the government's first step toward allowing the sale of follow-on versions of biotech drugs. The agency, which plans to publish more guidelines for specific biologic product classes, says existing laws authorize it to clear subsequent-entry products until legislation creates a new approval path.

Full Story:

Related Summaries